Reviewing and evaluating research proposals and projects, and reviewing and editing manuscripts submitted by top global researchers provides me with an opportunity to contribute while expanding my own horizons and sharpening my analytical skills.
I am deeply interested in the complex process of evaluating grant proposals. Insight gained during evaluations provides me with an immeasurably improved starting position for my own grant applications as seen in the success of the recent proposals for an EU FP7 and two IMI grants. In just the last few years, I have evaluated extensive proposals for NIH and the European Council (Innovative Medicines Initiative, and FP7 EU funded projects) as well as the Austrian Funding Agency (Austria Wirtschaftsservice Gesellschaft), the Greek governmental agency Agency for the Management & Implementation of Research, Technological Development & Innovation Actions, the Dutch ZonMw’s ‘Priority Medicines Antimicrobiële Resistentie’ programme.
My advice and input into European FP7 funded and IMI projects has been highly valued and my role as a member of the external advisory board of the EU funded project “IMPLEMENT” has been recognized.
I have been a member of the editorial board of Antimicrobial Agents and Chemotherapy 2006-2014. My collaboration with the editor-in-chief of the International Journal of Antimicrobial Agents, A.M. Geddes, has been longstanding and mutually beneficial and I have been a member of Geddes editorial board 2007-2015.
On both regular and ad-hoc basis, I review submissions for the Journal of Antimicrobial Chemotherapy, Lancet Infectious Diseases, European Journal of Infectious Diseases, Critical Care Medicine, Anesthesiology, Clinical Pharmacokinetics, Drugs, Research Microbiology, Recent Patents on Anti-Infective Drug Discovery, Trends in Pharmacological Sciences, Surgical Infections, the British Journal of Pharmacology, and British Medical Journal.
Since many years I am part of the reviewer team for the yearly ECCMID Conference. Since 2014, I am member of the ECCMID Programme Committee and specifically responsible for the areas PK/PD, dosing, and antibacterial drug R&D.